Here is an article detailing the news from Business Wire:
PCI Pharma Services Embarks on Next Growth Phase with Strategic Investment from Bain Capital, Kohlberg, and Mubadala
Philadelphia, PA – July 15, 2025 – PCI Pharma Services, a leading global pharmaceutical contract development and manufacturing organization (CDMO), announced today a significant strategic investment from Bain Capital, Kohlberg & Company, and Mubadala Capital. This substantial capital infusion marks the beginning of an exciting new chapter for PCI, poised to accelerate its growth trajectory and further solidify its position as a key partner in the pharmaceutical and biotechnology industries.
The investment from these esteemed private equity firms underscores PCI Pharma Services’ strong market presence, robust operational capabilities, and its commitment to delivering high-quality, integrated solutions to its clients. PCI offers a comprehensive suite of services, including sterile injectable manufacturing, drug product development, sterile and non-sterile dose manufacturing, and clinical trial services, making it a vital contributor to bringing life-saving and life-enhancing therapies to market.
With this strategic backing, PCI Pharma Services is well-positioned to expand its global footprint, enhance its technological infrastructure, and broaden its service offerings. The company plans to leverage this investment to further invest in its people, processes, and facilities, ensuring it continues to meet the evolving needs of its pharmaceutical and biotech partners. This includes potential expansions in manufacturing capacity, advanced technological capabilities, and specialized development services.
“We are thrilled to partner with Bain Capital, Kohlberg, and Mubadala Capital,” said [Insert Name and Title of PCI Executive, e.g., Bill Mitchell, President and CEO of PCI Pharma Services]. “Their collective expertise in scaling businesses and their deep understanding of the life sciences sector will be invaluable as we enter this next phase of growth. This investment will empower us to accelerate our strategic initiatives, enhance our service offerings, and ultimately better serve our clients and the patients who rely on their therapies.”
Bain Capital, a global alternative asset manager known for its operational expertise and success in supporting portfolio companies through periods of significant expansion, brings a wealth of experience in driving strategic growth. Kohlberg & Company, a leading private equity firm with a long-standing track record of partnering with management teams to build industry-leading companies, also contributes significant strategic insight. Mubadala Capital, the asset management arm of Mubadala Investment Company, with its focus on strategic, long-term investments in high-growth sectors, further strengthens the partnership.
This collaborative effort is expected to drive innovation and operational excellence within PCI Pharma Services, enabling the company to respond effectively to the increasing demand for outsourced pharmaceutical development and manufacturing solutions. The partnership signifies a shared vision for the future of pharmaceutical services and a mutual commitment to supporting the advancement of global healthcare.
PCI Pharma Services remains dedicated to its core mission of providing reliable, high-quality services that help bring innovative medicines from development to commercialization. This strategic investment will undoubtedly fuel that mission, positioning PCI for continued success and making it an even more impactful partner in the global life sciences ecosystem.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘PCI Pharma Services entre dans sa prochaine phase de croissance avec un investissement stratégique de Bain Capital, Kohlberg et Mubadala’ at 2025-07-15 11:30. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.